In Situ Cyclopentenyl Cytosine Infusion for the Treatment of Experimental Brain Tumors

John J. Viola, Stuart Walbridge, Eric M. Oshiro, Edward H. Oldfield, Zvi Ram, Riad Agbaria, David G. Johns, James A. Kelley

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Cyclopentenylcytosine (CPEC; NSC 375575) is a pyrimidine nucleoside analogue that has potent antitumor effects when tested in vitro and also when tested in experimental tumors outside the central nervous system. CPEC exerts its antiproliferative effect through inhibition of CTP synthetase and consequent depletion of CTP and dCTP pools required for cell replication. Due to its poor penetration of the blood-brain barrier, CPEC has failed to demonstrate therapeutic efficacy in experimental brain tumors after systemic administration. We therefore examined the in vivo activation, distribution, and antitumor effect of CPEC after long-term regional infusion of the drug directly into experimental brain tumors in rats. HPLC analysis of CPEC incubated with homogenized human brain and brain tumor tissue showed minimal degradation of the drug over 24 h. Analysis of rat cerebral 9L gliosarcoma infused with tritium-labeled CPEC demonstrated intratumoral accumulation of the active metabolite CPEC-triphosphate and concomitant depletion of CTP to a much greater extent in tumor tissue than in the adjacent brain. Tumor tissue UTP also decreased, but no significant effects on other ribonucleoside triphosphates were detected. Only trace amounts (<1%) of CPEC and its metabolites reached peripheral sites, including the liver and kidneys, after intratumoral infusion. Rats treated with continuous intratumoral infusion of CPEC for 4 weeks using s.c. implanted osmotic pumps survived significantly longer than control rats receiving intratumoral saline or i.p. CPEC (P < 0.0001). Long-term intratumoral infusion of CPEC was not associated with any detectable toxicity. Our results support the feasibility of using intratumoral administration of CPEC as a regional therapy for malignant brain tumors.

Original languageEnglish
Pages (from-to)1306-1309
Number of pages4
JournalCancer Research
Volume55
Issue number6
StatePublished - 15 Mar 1995
Externally publishedYes

Fingerprint

Dive into the research topics of 'In Situ Cyclopentenyl Cytosine Infusion for the Treatment of Experimental Brain Tumors'. Together they form a unique fingerprint.

Cite this